| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5685904 | Asian Journal of Urology | 2017 | 7 Pages |
Abstract
Based on the available survival data and current costs of treatment, all treatment strategies greatly exceed a commonly assumed societal willingness-to-pay threshold of US$100,000 per LYS. Improvements in this regard can only come with a reduction in pricing, better tailoring of treatment or significant enhancements in survival with clinical use of treatment combinations or sequences.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Matthew E. Pollard, Alan J. Moskowitz, Michael A. Diefenbach, Simon J. Hall,